Statin use and risk of new-onset diabetes: A meta-analysis of observational studies

Autor: G Corrao, Alberico L. Catapano, Manuela Casula, Elena Tragni, Francesco Mozzanica, Lorenza Scotti, Angela Pirillo
Přispěvatelé: Casula, M, Mozzanica, F, Scotti, L, Tragni, E, Pirillo, A, Corrao, G, Catapano, A
Rok vydání: 2017
Předmět:
Blood Glucose
Endocrinology
Diabetes and Metabolism
Medicine (miscellaneous)
030204 cardiovascular system & hematology
law.invention
0302 clinical medicine
Randomized controlled trial
Risk Factors
law
Nutrition and Dietetic
Odds Ratio
030212 general & internal medicine
Nutrition and Dietetics
Incident diabete
Diabetes Mellitu
Lipid
Lipids
Observational Studies as Topic
030220 oncology & carcinogenesis
Meta-analysis
Cohort
Cardiology and Cardiovascular Medicine
Risk assessment
Human
medicine.drug
medicine.medical_specialty
Statin
medicine.drug_class
Risk Assessment
03 medical and health sciences
Diabetes mellitus
Internal medicine
Diabetes Mellitus
medicine
Humans
Meta-analysi
Rosuvastatin
Dyslipidemias
business.industry
Risk Factor
Biomarker
Publication bias
Odds ratio
medicine.disease
Observational studie
Dyslipidemia
Observational study
Hydroxymethylglutaryl-CoA Reductase Inhibitor
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Biomarkers
Zdroj: Nutrition, Metabolism and Cardiovascular Diseases. 27:396-406
ISSN: 0939-4753
DOI: 10.1016/j.numecd.2017.03.001
Popis: Background and aims Meta-analyses of randomized control trials investigating the association between incident diabetes and statin use showed an increased risk of new-onset diabetes (NOD) from 9% to 13% associated with statins. However, short follow-up period, unpowered sample size, and lack of pre-specified diagnostic criteria for diabetes detection could be responsible of an underestimation of this risk. We conducted a meta-analysis of published observational studies to evaluate the association between statins use and risk of NOD. Methods and results PubMed, EMBASE and MEDLINE databases were searched from inception to June 30, 2016 for cohort and case–control studies with risk of NOD in users vs nonusers, on ≥1000 subjects followed-up for ≥1 year. Two review authors assessed study eligibility and risk of bias and undertook data extraction independently. Pooled estimates were calculated by a random-effects model and between-study heterogeneity was tested and measured by I 2 index. Furthermore, stratified analyses and the evaluation of publication bias were performed. Finally, the meta-analysis included 20 studies, 18 cohort and 2 case–control studies. Overall, NOD risk was higher in statin users than nonusers (RR 1.44; 95% CI 1.31–1.58). High between-study heterogeneity (I 2 = 97%) was found. Estimates for all single statins showed a class effect, from rosuvastatin (RR 1.61; 1.30–1.98) to simvastatin (RR 1.38; 1.19–1.61). Conclusions The present meta-analysis confirms and reinforces the evidence of a diabetogenic effect by statins utilization. These observations confirm the need of a rigorous monitoring of patients taking statins, in particular pre-diabetic patients or patients presenting with established risk factors for diabetes.
Databáze: OpenAIRE
Externí odkaz: